About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

New Gene Target Identified for Treating Epithelial Ovarian Cancer

by Hannah Joy on September 30, 2017 at 11:10 AM
Font : A-A+

New Gene Target Identified for Treating Epithelial Ovarian Cancer

KPNB1 is the new gene target for treating epithelial ovarian cancer (EOC), reveals a new study.

EOC is the fifth leading cause of cancer-related deaths in women and has a particularly grim outlook upon diagnosis. They also find that ivermectin exerts an anti-tumor effect on EOC cells by interacting with the KPNB1 gene.

Advertisement


Because ivermectin is already approved to treat parasitic infections in patients, experiments for its effectiveness in an anti-cancer regimen is expected to significantly lower costs compared to untested drug compounds. Osaka Researchers, in partnership with other Japanese and U.S. scientists report the study in Proceedings of the National Academy of Sciences.

"EOC is a challenging disease to treat because of its heterogeneity. The mortality rate has stayed steady for decades. We need new drugs and also new drug targets," says Osaka University Gynecologist Michiko Kodama, who first-authored the study.
Advertisement

To search for new drug target genes for EOC, Kodama did two in vivo screenings, one shRNA based and the other CRISPR/Cas9 based. Several were found including ERBB2, but because there are already drugs that target ERBB2 in clinical use, she settled her attention on the gene with the second highest rank in the screening, KPNB1.

Kodama confirmed that KPNB1 has features consistent of an oncogene, finding that its overexpression significantly accelerated EOC cell proliferation and survival, while its inhibition induced apoptosis.

"We found KPNB1 activation and inhibition had a direct effect on the expression of apoptosis factors," she says.

Adding to the likelihood that this gene has a role in EOC, she found that the prognosis for EOC patients diminished with higher KPNB1 expression.

"This does not show KPNB1 is a cause of EOC, but it does show it could be a target", she added.

It has been estimated that drug repositioning takes one third the time and cost for an experimental drug to receive federal approval compared with drug discovery. Therefore, to find drug candidates that can suppress the oncogenetic properties of KPNB1, Kodama sought only clinically-approved drugs, settling on ivermectin.

"Ivermectin inhibits importin /-mediated nuclear transport. KPNB1 is a member of the importin family," she explains, adding that this family imports proteins into the cell nucleus.

She found that ivermectin had pro-apoptotic effects in EOC cells, but not if the KPNB1 activity was already artificially suppressed. Moreover, ivermectin had a synergistic effect when combined with paclitaxel, the currently preferred drug for EOC treatment.

Because EOC cancer is heterogeneous, the best therapeutic regimens will likely involve a combination of drugs. Through comprehensive screenings for mutants and clinically-approved drugs, Kodama is hopeful that drug repositioning will bring such regimens to patients faster. "We do not understand the molecular mechanisms for the synergistic effect. Ivermectin and paclitaxel have been in clinical use for several decades, which should facilitate clinical trials," she said.



Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Advertisement
News Category
What's New on Medindia
International Day of Persons with Disabilities 2021 - Fighting for Rights in the Post-COVID Era
Effect of Blood Group Type on COVID-19 Risk and Severity
Woman with Rare Spinal Cord Defect from Birth Sues Doctor
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
DNA Finger Printing Ovarian Cancer Cancer and Homeopathy Cancer Facts Cancer Tattoos A Body Art Weaver Syndrome Meigs Syndrome Ovarian Pain Premature Ovarian Failure 

Recommended Reading
Growth and Metastases of Epithelial Ovarian Cancer is Promoted by Scaffolding Protein
A scaffolding protein called NEDD9 responsible for regulating signaling pathways in the cell has ......
Therapeutic Targets to Reverse Chemoresistance in Epithelial Ovarian Cancer
Epithelial ovarian cancer is a disease in which malignant cells form in the tissue covering the ......
Genetic Subtypes Linked to Increased Risk of Developing Ovarian Cancer
Women with certain types of human leukocyte antigen (HLA) may have an increased risk of ovarian ......
DNA Finger Printing
DNA fingerprinting is a technique which helps forensic scientists and legal experts solve crimes, id...
Meigs Syndrome
Meigs'' syndrome is a medical condition with a triad of symptoms including benign ovarian tumor, asc...
Ovarian Cancer
Ovarian cancer affects both the ovaries and is referred to as the ''silent killer'' as the symptoms ...
Ovarian Pain
Ovarian pain is caused due to various conditions like ovarian cysts, ovarian tumors, endometriosis, ...
Premature Ovarian Failure
Premature menopause is ovarian failure which occurs 2 SD in years before a mean menopausal age and p...
Tattoos A Body Art
Tattoos are a rage among college students who sport it for the ‘cool dude’ or ‘cool babe’ look...
Weaver Syndrome
Weaver syndrome is a genetic disorder in which children show accelerated bone growth, advanced bone ...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use